Creutzfeldt-Jakob disease: hopes for therapy

Rapidly progressive dementias and the treatment of human prion diseases

IMPORTANCE OF THE FIELD

Rapidly progressive dementia (RPD) has many possible etiologies and definitive treatment is reliant upon an accurate diagnosis from an appropriate diagnostic work-up. A large portion of the neurodegenerative causes of RPD are due to prion diseases (e.g., Creutzfeldt-Jakob disease). The study of prion diseases, for which there is no currently available treatment, has public health implications and is becoming increasingly more relevant to our understanding of other protein misfolding disorders including Alzheimer's disease, frontotemporal degeneration, and Parkinson's disease.

AREAS COVERED IN THIS REVIEW

This article begins with an overview of the etiologies and diagnostic work-up of RPD followed by a detailed review of the literature concerning the treatment of human prion diseases (1971 to present).

WHAT THE READER WILL GAIN

The reader will understand the differential diagnosis and work-up of RPD as it pertains to its treatment, as well as an in-depth understanding of treatments of human prion diseases.

TAKE HOME MESSAGE

An accurate diagnosis of the cause of RPD is of paramount importance when determining appropriate treatment. Most studies of the treatment for human prion diseases are case reports or case series, and results from only one randomized, placebo-controlled study have been reported in the literature (flupirtine). Studies have been hindered by disease heterogeneity and lack of standardized outcome measures. Although no effective prion disease treatment has been revealed through these studies, they provide important considerations for future studies.

Genomic and post-genomic analyses of human prion diseases

Prion diseases share common features of neurodegenerative disorders, infectious diseases and pathologies linked to misfolded proteins. Whether these aspects are independently and fortuitously present in prion diseases or are somewhat linked together remains unsettled, but the contribution of genomic, proteomic, metabolomic and spectroscopic techniques might give insights into this puzzle, and likely give hope for therapy to patients. Although the prion protein gene (PRNP) governs most of the clinical and pathological features of prion diseases and plays a pivotal role in determining host susceptibility, there are still many uncertainties and unknown risk factors that need to be clarified and identified. Several genes, other than PRNP, have recently been found to be associated with a risk of developing sporadic or variant Creutzfeldt-Jakob disease, but these novel data have been produced in a relatively small number of patients and controls and, therefore, need further confirmation. The same criticism applies to the identification of the over 20 new cerebrospinal fluid or plasma markers of disease. Some of these markers seem related to the massive brain damage that occurs, rather than being specific to prion infection. Nevertheless, genomic and post-genomic approaches have shown that these techniques are very powerful, and the best way to overcome the scantiness of samples would be to encourage strong collaboration between different centers of excellence in prion diseases. In this review, we describe the most recent and outstanding advances offered by genomics and post-genomics analyses in the field of human prion diseases.

Clinical features and diagnosis of human prion diseases

Human prion diseases are a group of progressive, fatal encephalopathies united by their similar neuropathological features, their potential transmissibility and a core molecular feature: a conformational change in prion protein. They exist in sporadic/idiopathic, genetic and acquired forms. The clinical features vary according to a number of factors, including cause and the prion protein genotype of the affected individual. Common features include dementia, cerebellar ataxia and involuntary movements. There is no absolute clinical diagnostic test; definitive diagnosis is neuropathological. However, MRI, electroencephalogram, cerebrospinal fluid protein tests, genetic tests and tonsil biopsy, can be very helpful in supporting a clinical diagnosis. The development of a noninvasive diagnostic test (e.g., on blood) would be very helpful in terms of easier, earlier clinical diagnosis, as well as having other applications (such as blood donor screening or population infection prevalence surveys). A relatively new technique (protein misfolding cyclic amplification) holds promise as such a test. Various therapeutic approaches have been suggested, but there is no current effective treatment and there are significant problems in the assessment of any candidate therapies.